Inclusion Criteria:

- aged over 20 years or older

- histologically confirmed metastatic and/or unresectable urothelial carcinoma arising
from bladder, ureter, or renal pelvis

- ECOG performance status of 0 or 1

- measurable disease, or evaluable lesion(s), as defined by RECIST

- clinical failure of the prior chemotherapy for advanced disease, including
gemcitabine and platinum

- adequate major organ functions

- written informed consent

Exclusion Criteria:

- severe co-morbid illness and/or active infections

- prior treatment with taxanes (paclitaxel and docetaxel)

- any patients judged by the investigator to be unfit to participate in the study